Key result
Higher cystatin C linked to ~196% higher risk of incident CKD and mortality in non-diabetics.
Why the study?
Is higher cystatin C associated with an increased risk of incident CKD and all-cause mortality in non-diabetic patients with normal or mildly reduced renal function?
Cohort (n=146)
No
Is higher cystatin C associated with an increased risk of incident CKD and all-cause mortality in non-diabetic patients with normal or mildly reduced renal function?
Hazard Ratio: 2.96 (95% CI 1.09–8.09)
p-value: p=0.034
Higher cystatin C levels are an independent predictor of incident CKD and all-cause mortality in non-diabetic patients, particularly those with prediabetes.
May identify higher-risk non-diabetics for closer monitoring; leaves open whether cystatin C adds value beyond eGFR.
We investigated the association of cystatin C with incident chronic kidney disease (CKD), defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m 2 . We enrolled patients with an eGFR ≥ 60 mL/min/1.73 m 2 who underwent an oral glucose tolerance test (OGTT) between 2011 and 2013. Patients with diabetes were excluded from the analysis. We measured their cystatin C levels, and all patients’ renal function and survival status were followed until March 2023. Cox-proportional hazard models were conducted to examine the association of cystatin C with incident CKD and all-cause mortality. A total of 146 patients were analyzed. After a median follow-up period of 10.7 years, patients with a higher cystatin C (≥ median vs. < median) were independently associated with a higher risk of incident CKD and all-cause mortality (adjusted hazard ratio [HR] 2.96, 95% CI 1.09 to 8.09, p = 0.034). The findings were consistent when cystatin C was analyzed as a continuous variable. The association was mainly observed in patients with prediabetes (adjusted HR 5.75, 95% CI 1.34 to 24.69, p = 0.019). In summary, a higher cystatin C was independently associated with risk of incident CKD and all-cause mortality in non-diabetes patients with an eGFR ≥ 60 mL/min/1.73 m 2 .
No takes yet. Share an insight, caveat, or question.
Lin et al. (2025) conducted a cohort in Normal glucose tolerance and prediabetes (n=146). Higher cystatin C (≥ median) vs. Lower cystatin C (< median) was evaluated on Incident chronic kidney disease and all-cause mortality (HR 2.96, 95% CI 1.09 to 8.09, p=0.034). Higher cystatin C levels (≥ median) were independently associated with a higher risk of incident chronic kidney disease and all-cause mortality (adjusted HR 2.96) in non-diabetes patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: